StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd.

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)

Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –

BeOne Medicines External R&D — R&D Collaboration Projects by Year

External R&D — R&D Collaboration Projects ($M) ($M)

BeOne Medicines External R&D — R&D Collaboration Projects: $105M in FY2025, down 44.6% from a year earlier.

Latest, FY2025
105
Period ended Dec 31, 2025
Change on a year earlier
-44.6%
189 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below

Where the FY2025 figure comes from

“|| R&D collaboration projects | 104,852 | 189,214”

Reported in Form 8-K EX-99.1 SSE STAR Market Annual Reports (688235.SS).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedExternal R&D — R&D Collaboration Projects ($M) ($M)Year on yearSource
FY2025Dec 31, 2025105-44.6%8-K STAR Report (2026-04-14, 0001651308-26-000008) ↗
FY2024Dec 31, 2024189+89.0%8-K STAR Report (2026-04-14, 0001651308-26-000008) ↗
FY2023Dec 31, 2023100-40.3%8-K STAR Report (2025-04-28, 0001651308-25-000057) ↗
FY2022Dec 31, 2022168-15.8%8-K STAR Report (2024-04-26, 0001651308-24-000043) ↗
FY2021Dec 31, 2021199-12.2%8-K STAR Report (2023-04-25, 0001651308-23-000061) ↗
FY2020Dec 31, 2020227+353.0%8-K STAR Report (2022-04-28, 0001651308-22-000058) ↗
FY2019Dec 31, 201950-43.8%8-K STAR Report (2021-11-16, 0001651308-21-000229) ↗
FY2018Dec 31, 201889–8-K STAR Report (2021-11-16, 0001651308-21-000229) ↗

Cite this data

StockData. (2026). BeOne Medicines External R&D — R&D Collaboration Projects ($M), annual FY2018–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-mol-collab

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.